O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+15.9%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$6.71B
AUM Growth
+$6.71B
(+24%)
Cap. Flow
+$780M
Cap. Flow
% of AUM
11.63%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
137
New
19
Increased
49
Reduced
25
Closed
20
Top Buys
| 1 |
RLYP
RELYPSA INC COM
RLYP
|
$249M |
| 2 |
Perrigo
PRGO
|
$119M |
| 3 |
AbbVie
ABBV
|
$107M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$83.9M |
| 5 |
CELG
Celgene Corp
CELG
|
$76.1M |
Top Sells
| 1 |
Merck
MRK
|
$177M |
| 2 |
Elevance Health
ELV
|
$71.8M |
| 3 |
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
|
$56.2M |
| 4 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
$56.1M |
| 5 |
SPDR S&P 500 ETF Trust
SPY
|
$50.4M |
Sector Composition
| 1 | Healthcare | 84.81% |
| 2 | Financials | 1.2% |
| 3 | Technology | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $375M | 5.51% | 4,992,600 +214,800 | +4% | +$16.1M |
|
2
Biogen
BIIB
$19.4B
| $306M | 4.5% | 1,095,100 +68,700 | +7% | +$19.2M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $297M | 4.36% | 1,757,100 +450,100 | +34% | +$76.1M |
|
4
Bristol-Myers Squibb
BMY
$96B
| $290M | 4.27% | 5,465,000 +261,000 | +5% | +$13.9M |
|
5
Amgen
AMGN
$155B
| $287M | 4.22% | 2,515,300 -114,300 | -4% | -$13M |
|
|
RLYP
6
DELISTED
RELYPSA INC COM
RLYP
| $249M | 3.65% | +9,941,549 | New | +$249M |
|
7
Incyte
INCY
$16.5B
| $206M | 3.03% | 4,069,000 -404,000 | -9% | -$20.5M |
|
8
Regeneron Pharmaceuticals
REGN
$61.5B
| $203M | 2.99% | 738,800 +225,700 | +44% | +$62.1M |
|
|
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
| $199M | 2.93% | 3,123,500 +839,000 | +37% | +$53.5M |
|
|
10
AbbVie
ABBV
$372B
| $199M | 2.92% | 3,760,900 +2,018,900 | +116% | +$107M |
|
11
Viatris
VTRS
$12.3B
| $183M | 2.69% | 4,214,500 -834,500 | -17% | -$36.2M |
|
12
HCA Healthcare
HCA
$94.5B
| $179M | 2.64% | 3,758,000 +705,000 | +23% | +$33.6M |
|
13
Illumina
ILMN
$15.8B
| $177M | 2.6% | 1,596,800 +3,000 | +0.2% | +$332K |
|
14
Agilent Technologies
A
$35.7B
| $173M | 2.54% | 3,017,600 +771,600 | +34% | +$44.1M |
|
15
Thermo Fisher Scientific
TMO
$186B
| $171M | 2.51% | 1,534,200 -11,800 | -0.8% | -$1.31M |
|
|
16
Merck
MRK
$210B
| $127M | 1.87% | 2,547,000 -3,529,000 | -58% | -$177M |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $120M | 1.76% | 713,000 +237,900 | +50% | +$40M |
|
|
18
Perrigo
PRGO
$3.27B
| $119M | 1.74% | +773,000 | New | +$119M |
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $118M | 1.74% | 1,734,934 -416,673 | -19% | -$28.5M |
|
|
ITMN
20
DELISTED
INTERMUNE INC
ITMN
| $113M | 1.67% | 7,697,000 +4,809,400 | +167% | +$70.8M |
|
21
Pfizer
PFE
$141B
| $109M | 1.6% | 3,553,000 -457,400 | -11% | -$14M |
|
22
Insulet
PODD
$23.9B
| $107M | 1.57% | 2,888,500 +36,000 | +1% | +$1.34M |
|
|
IPXL
23
DELISTED
Impax Laboratories, Inc.
IPXL
| $107M | 1.57% | 4,237,600 +951,900 | +29% | +$23.9M |
|
|
SHPG
24
DELISTED
Shire pic
SHPG
| $102M | 1.5% | 724,000 +33,100 | +5% | +$4.68M |
|
25
BioMarin Pharmaceuticals
BMRN
$11.2B
| $99.5M | 1.46% | 1,414,100 -167,600 | -11% | -$11.8M |
|